Bifogade filer
2025-H1 - Lytix Biopharma - Interim Report - IFRS - 2025-06-30 - Final
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2025-08-28 07:00:00
Oslo, Norway, August 28, 2025 - Lytix Biopharma AS, a clinical-stage
immuno-oncology company, today announced its results for the second quarter and
first half of 2025.
The first half of the year has been a period of steady clinical progress and
preparation. Lytix advanced across clinical, regulatory and organizational
priorities, building a stronger foundation for the decisive period ahead.
- Over the past years, we have validated Lytix technology across several cancer
types and indications with strong results in a variety of patient populations.
Our technology has demonstrated proof-of-concept across various skin cancers,
highlighting a significant and urgent need for new treatment alternatives. The
gap in today's treatment options is positioning Lytix and our drug candidates at
the forefront for cancer treatment of tomorrow, said Dr. Øystein Rekdal, CEO of
Lytix Biopharma.
At the center of this progress is Ruxotemitide (formerly LTX-315). The program
has matured with the assignment of its international nonproprietary name (INN),
a successful End-of-Phase II FDA meeting for basal cell carcinoma through
partner Verrica, and completion of patient treatment in the ATLAS-IT-05 trial in
advanced melanoma. In parallel, enrollment is progressing in the NeoLIPA study
in early-stage melanoma, with interim results expected in November 2025.
These clinical steps are complemented by a strengthened leadership team and
board, reflecting Lytix's transition from clinical exploration toward late-stage
development, partnering, and future commercialization.
- We are moving step by step toward patients. With the completion of our
advanced melanoma trial and progress in early-stage melanoma, Ruxotemitide is
transitioning into earlier disease settings where therapeutic potential is
greater. Alongside our partner Verrica's preparations for Phase III in basal
cell carcinoma, the coming months will be a milestone-rich period for Lytix,
said Rekdal.
H1 2025 highlights and developments
o Licensing partner Verrica Pharmaceuticals had a successful end-of-phase II FDA
meeting for Ruxotemitide in basal cell carcinoma